Impact of Baseline Characteristics on Geographic Atrophy Progression in the FILLY Trial Evaluating the Complement C3 Inhibitor Pegcetacoplan

PurposeTo evaluate the effect of select baseline characteristics on geographic atrophy (GA) progression in eyes receiving intravitreal pegcetacoplan or sham.DesignPhase 2 multicenter, randomized, single-masked, sham-controlled trial.MethodsPatients with GA received 15 mg monthly every other month (EOM), sham injection EOM for 12 months. Primary efficacy endpoint was change lesion size (square root) from baseline. Post hoc analysis evaluated effects age; gender; size, focality, and location (extrafoveal vs foveal); pseudodrusen status; best-corrected visual acuity (BCVA); low-luminance deficit (LLD) at Month 12.ResultsOf 246 randomized patients, 192 12-month data were included this analysis. Overall mean (standard deviation) (mm) 0.26 (0.17) (P < .01), 0.27 (0.27) .05), 0.36 (0.21) (n = 67), 58), 67) groups, respectively. In univariate analysis, patients extrafoveal lesions .001), BCVA ≥20/60 larger LLD .002) had greater changes size. Multivariate confirmed significant association .001) .023) progression. Monthly significantly reduced .05) when controlling these risk factors.ConclusionsExtrafoveal are potential factors Pegcetacoplan treatment controlled even after accounting factors. To sham. Phase trial. Patients 12. Of Extrafoveal